Introduction {#s1}
============

The chemokines CX3CL1/fractalkine and CXCL16 are transmembrane (*tm*) proteins ([@bib3]; [@bib30]) that are converted to soluble ligands by metalloproteinases, in particular ADAM10 and ADAM17 (a disintegrin and metalloproteinase, [@bib11]; [@bib21]; [@bib1]; [@bib28]). These soluble (*s-*) chemokines induce signal transduction and chemotaxis in target cells which express their classical G protein-coupled receptors CX3CR1 and CXCR6/Bonzo; however, also firm adhesion between *tm-*chemokine- and chemokine-receptor-bearing cells has been reported ([@bib22]; [@bib48]). Of note, both chemokines themselves, show potential signal transduction sites in their short intracellular domains, but so far signaling via the transmembrane forms has not been described ([@bib3]; [@bib30]).

In contrast, several transmembrane ligands themselves are known to transduce signals after binding of their respective receptor. This reverse transduction of signals by transmembrane ligands has been initially observed with ligands of the tumor necrosis factor (TNF) family after binding to their cognate receptors (or to antibodies), and thus bidirectional responses are produced ([@bib7]; [@bib6]; [@bib27]). This principle has been also described for IL-15 ([@bib32]), ephrin-ligands ([@bib26]) and semaphorins ([@bib51]). Reverse signaling can induce several biological functions, e. g. co-stimulation, silencing, transmission of additional signals ([@bib6]; [@bib43]), or synapse formation and plasticity in the nervous system ([@bib26]). Reverse signaling may thus be an alternative to an autocrine-signaling loop with classical receptors. So far, reverse signaling has only been reported for distinct transmembrane ligand molecules although signaling motifs for reverse signaling are more abundant and also found within the transmembrane variants of the chemokine family.

Investigating the role of transmembrane chemokines in cancer, we detected a remarkable high synthesis in several types of tumor cells without an appropriate expression of their classical receptors ([@bib17]; [@bib15]). Therefore, we looked for alternative functions and receptors. We found that cells expressing high levels of a *tm-*chemokine also responded to their soluble counterparts without expressing the respective G protein-coupled chemokine receptor. Further detailed investigations revealed that *tm-*chemokines themselves, in fact, responded to soluble chemokines via a novel mechanism by binding their soluble forms and subsequently inducing signals and functional responses. We propose that this novel mechanism leads to auto- or paracrine activation of cells expressing *tm*-chemokines that either function as surface receptor or can be shed to generate soluble ligands of another *tm*-chemokine on the cell surface.

Results {#s2}
=======

Transmembrane chemokines are highly expressed in several types of tumor cells {#s2-1}
-----------------------------------------------------------------------------

By quantitative RT-PCR we detected high levels of CXCL16 and CX3CL1 in human glioma, neuroblastoma, colon carcinoma, lower levels in breast cancer cells, and LOX melanoma cells produced very low or non-detectable mRNA amounts ([Figure 1](#fig1){ref-type="fig"} upper panel; Δ C~T~ in logarithmic scale, thus a 3.3 higher Δ C~T~value indicates a 10-fold lower expression). Beside tumor cells, also endothelial cells and monocytes like THP-1 cells express *tm*-chemokines. In contrast to this broad distribution of ligands, the expression of the receptors CXCR6 and CX3CR1 was restricted to only a few cell types, e.g. activated T-cells (positive control, compare [@bib28]) or monocytes/monocytic THP-1 cells. The expression of CX3CL1 and CXCL16 was confirmed on protein level by immunocytochemistry (lower panel of [Figure 1](#fig1){ref-type="fig"}), which revealed high expression for the brain tumor cell lines and low expression for the breast carcinoma cell line MCF-7. The LOX melanoma cell line showed no protein expression, and therefore was chosen as a control cell line in the subsequent experiments. CXCR6 and CX3CR1 were not detectable in the solid tumor cell lines on protein level either (not shown) by immunocytochemistry using antibodies that were suitable for this application in recent investigations ([@bib17]; [@bib15]). Although these axes of transmembrane chemokines together with their receptors can play important roles in selected tumor-stroma cell interactions, the circumscribed lack of receptors in brain tumor cells themselves contrasts the broad and high expression of chemokines that has also been shown for gliomas and schwannomas *in* situ ([@bib17]; [@bib15]; [@bib18]).10.7554/eLife.10820.003Figure 1.Expression of transmembrane chemokines and their known receptors in various cell types.**Top:** As determined by qRT-PCR, the transmembrane chemokines CXCL16 and CX3CL1 are highly transcribed in many human tumor cell lines including glioma (U118, U343, T98G, A172, A764), colon carcinoma (HT29)and neuroblastoma cells (SH-SY5Y), in monocytes (THP-1) and in endothelial cells (HUVEC), at lower levels in breast cancer cells (MCF-7), but not/negligible in LOX melanoma. OH3 small cell lung cancer cells produced CX3CL1, but not CXCL16. In contrast, the known receptors CXCR6 or CX3CR1 were only detectable in a sample of activated T cells or in THP-1 cells, but not in tumor or endothelial cells (n = 3 biological replicates, single data indicated by diamonds). **Bottom:** Immunostaining of a selection of tumor cells exemplarily confirms cell specific protein expression levels of the transmembrane chemokines, and their absence in LOX melanoma cells. Micrographs were taken with exposure times of 600 ms (CXCL16) or 800 ms (CX3CL1, secondary antibody control \[sec ab\]) for each cell line. Bars indicate 20 µm, n = 3 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.003](10.7554/eLife.10820.003)

Receptor-negative, *tm*-chemokine-expressing cells can be stimulated by soluble chemokines {#s2-2}
------------------------------------------------------------------------------------------

When cells negative for the known receptors CXCR6 and CX3CL1 (compare [Figure 1](#fig1){ref-type="fig"}) were stimulated with *s*-CXCL16 or *s*-CX3CL1, we could, however, detect a transient, dose-and time-dependent phosphorylation of kinases and further biological effects ([Figures 2A,B](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). In all tested cells that expressed *tm*-chemokines (like U343, A172, A764, T98G glioma cell lines, primary glioma cells, or HT29 colon carcinoma cells; not all shown) phosphorylation of ERKs (extracellular signal-regulated kinase, p42/p44) occurred after 10-40 min using concentrations from 0.01 to 10 nM with maximum responses at about 1 nM. By contrast, in *tm*-chemokine-negative and receptor-negative LOX melanoma cells no signal transduction was observed ([Figure 2C](#fig2){ref-type="fig"}). These signal transduction effects on *tm*-chemokine-positive cells did not depend on the source of recombinant *s*-chemokines (not shown). Furthermore, not only cell lines but also primary cells isolated from surgically dissected human gliomas were responsive, which express -- as the cell lines -- *tm*-chemokines, but not their classical receptors ([Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.10820.004Figure 2.Signal transduction in receptor-negative (CXCR6^-^, CX3CR1^-^) tumor cells after stimulation with soluble chemokines (1 nM *s-*CXCL16 or *s-*CX3CL1).**A**) As shown by Western blots after SDS-PAGE separation, receptor-negative but hence responsive cell lines like the glioma cell lines U343, A764, T98G and primary glioma cultures from different patients display a time- and dose-dependent phosphorylation of the kinase ERK (extracellular signal-regulated kinase p42/p44) after stimulation with *s*-chemokines for the indicated times (compare also [Figure 2 - figure supplement 1](#fig2s1){ref-type="fig"}). The responsiveness coincidences with the presence or absence of the corresponding *tm*-chemokines; compare [Figure 1](#fig1){ref-type="fig"}. Stimulation with epidermal growth factor (EGF; 2 nM) serves as a positive phosphorylation control. Re-blot against non-phosphorylated kinase ERK2 ensures equal loading of the lanes. (**B**) Immunostaining of *s*-chemokine-stimulated U343 or A764 glioma cells confirms the time-dependent phosphorylation of ERK (rabbit anti-pERK 1/2 with secondary antibody Alexa-Fluor 555 (red)-anti-rabbit IgG; blue nuclear counterstaining with DAPI). Bars indicate 20 µm. (**C**): The *tm*-chemokine negative LOX melanoma cells are not responsive to 1 nM *s*-chemokines, ERK-phosphorylation is only observed in positive control samples stimulated with epidermal or fibroblast growth factors (EGF or FGF-2, 2 nM). All shown data are representative results from 2-3 independent experiments, respectively, for biological replicates please refer to [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.004](10.7554/eLife.10820.004)10.7554/eLife.10820.005Figure 2---figure supplement 1.Biological replicates of western blot experiments showing time- and dose-dependent activation of ERK1/2 upon stimulation with s-chemokines in responsive glioma cell lines (compare [Figure 2A](#fig2){ref-type="fig"})**DOI:** [http://dx.doi.org/10.7554/eLife.10820.005](10.7554/eLife.10820.005)10.7554/eLife.10820.006Figure 2---figure supplement 2.Biological replicates of western blot experiments showing stimulations of non-responsive LOX melanoma cells with s-chemokines (compare [Figure 2C](#fig2){ref-type="fig"})**DOI:** [http://dx.doi.org/10.7554/eLife.10820.006](10.7554/eLife.10820.006)10.7554/eLife.10820.007Figure 3.Biological effects after stimulation of receptor-negative (CXCR6^-^, CX3CR1^-^) tumor cells with soluble chemokines (1 nM *s-*CXCL16 or *s-*CX3CL1).**Top:** Soluble chemokines (1 nM) enhance proliferation of U343 and A764 glioma cells expressing the transmembrane counterparts, but not of LOX melanoma cells that are *tm*-chemokine negative. Stimulation was performed for 24 hr and proliferation analyzed by WST-assay. As positive control, growth medium (med.) with 10% fetal calf serum (FCS) was used. Mean values ± standard deviations of at least 3 independent biological replicates (indicated as diamonds) are shown. Moreover, both *s*-chemokines (1 nM, respectively) reduced caspase-3/7 activity evoked by the chemotherapeutic Temozolomide (400 µg/ml, from stock solution in dimethylsulfoxide, DMSO). Stimulations were performed for 48 hr, controls were supplemented with 2% DMSO (corresponding to the solvent concentration in Temozolomide-stimulated samples). Caspase 3/7 activity was measured by fluorescence of the converted substrate in 3 independent biological replicates. Mean values ± standard deviations are shown. For effects of the tm-chemokine low expressing cell line compare [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. **Bottom:** Migration of U343 and A764 glioma cells was not influenced by stimulation with 10 nM *s-*CXCL16 or *s-*CX3CL1 in a wound healing ('scratch') assay performed for the indicated times. 20% FCS served as positive control. Mean values ± standard deviations are shown from 2-3 independent biological replicates, for data of biological replicates compare [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}. Representative images are shown, bars indicate 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.007](10.7554/eLife.10820.007)10.7554/eLife.10820.008Figure 3---source data 1.Biological replicates of the scratch assay shown in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.008](10.7554/eLife.10820.008)10.7554/eLife.10820.009Figure 3---figure supplement 1.Only slight activation and effects upon *s*-chemokine stimulation of *tm*-chemokine low expressing MCF-7 cells.**Top**: MCF-7 breast carcinoma cells were stimulated with 1 nM *s-*CXCL16 or *s*-CX3CL1 for 20 min and subjected to Western blot on ERK1/2 phosphorylation. In comparison to positive controls (EGF and IGF-1, 10 min) *s-*chemokines exerted only slight activation of the MAP kinase pathway. In accordance, caspase 3/7 activity induced by 0.1 µM Staurosporine (15 hr) wasis only slightly reduced by co-stimulation with *s-*chemokines, and hardly robust (n = 3 independent experiments).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.009](10.7554/eLife.10820.009)

To ensure that the observed signal transduction also triggers biological effects, we investigated the influence of *s*-chemokines on cell proliferation, apoptosis and migration ([Figure 3](#fig3){ref-type="fig"}). Both chemokines, *s*-CXCL16 and *s*-CX3CL1, significantly enhanced proliferation of classical receptor-negative, *tm*-chemokine-positive cells like U343 or A764 glioma cells, whereas double-negative cells like LOX melanoma cells did not respond. Furthermore, stimulation with *s*-CXCL16 and *s*-CX3CL1 reduced caspase-3/7 activity that was induced by exposure to Temozolomide, a clinically used chemotherapeutic for gliomas. However, the classical biological effect of chemokines, namely cell migration, was not mediated by this signaling ([Figure 3](#fig3){ref-type="fig"} bottom, and [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

As a first hint to cell specificity and expression dependent response of the measured effects, the breast cancer cell line MCF-7, that displayed low expression levels of *tm*-chemokines (compare [Figure 1](#fig1){ref-type="fig"}), showed only a slight phosphorylation signals for ERK1/2 and a slightly reduction of caspase 3/7 activity (induced by Staurosporine) upon stimulation with the s-chemokines ( [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} ).To exclude that signal transduction and biological effects after stimulation with *s*-chemokines occurred through activation of other chemokine receptors, we inhibited the classical chemokine receptor G~i/o~-signaling in responsive glioma cells using *Pertussis* toxin. Pre-incubation with *Pertussis* toxin did not influence signal transduction of responsive *tm*-chemokine-positive cells ([Figure 4A](#fig4){ref-type="fig"}). Its inhibitory effect was confirmed in stimulations of CX3CR1^+^-THP-1 cells. Also, an engineered peptide receptor-antagonist of fractalkine ([@bib19]) mediated ERK phosphorylation in primary glioma cells comparable to the recombinant soluble peptide ([Figure 4A](#fig4){ref-type="fig"}, lower part). We additionally analyzed the expression profile of a broad panel of CXC-chemokine and decoy receptors. As shown in [Figure 4B](#fig4){ref-type="fig"}, glioma cell lines did not express CXCR3, CXCR4, CXCR6, CX3CR1, but high levels of CXCR7, which is a receptor for CXCL11 and CXCL12 and can mediate G-protein independent signals via arrestin ([@bib33]). However, inhibition of CXCR7 by the synthetic antagonist ([@bib14]; [@bib49]) CCX733 exhibited no influence on *tm*-chemokine signaling ([Figure 4C](#fig4){ref-type="fig"}). As chemokine decoy receptors (D6, DARC, CCX-CKR) were expressed in glioma as well as LOX cells, they could be ruled out as mediators for *tm*-chemokine effects that were absent in the melanoma cells. A viral encoded putative receptor for CX3CL1, US28 ([@bib29]), was detected neither in glioma cells, nor in LOX melanoma cells, and thus, can be excluded for *s-*CXCL16 or *s-*CX3CL1 signaling. Additionally, the expression of CD44, a receptor for hyaluronic acid and further ligands, e.g. CCL5 ([@bib38])was determined at comparable protein levels in glioma cells and melanoma cells. These findings as well as independence of *s-*chemokine-mediated signal transduction from *Pertussis* toxin suggest that classical G protein-coupled chemokine receptors are not involved in the described effects of *s*-chemokines. Furthermore, related CXC-receptors and chemokine decoy receptors are absent or can be excluded as functional receptors for *s*-CXCL16 or *s*-CX3CL1 as well as other types of receptors that require G~i/o~-association.10.7554/eLife.10820.010Figure 4.Inhibition experiments and transcription analysis exclude the involvement of other chemokine receptors.(**A**) *Pertussis* toxin (PTX, 200 ng/ml) inhibiting G~i/o~-signaling of classical chemokine receptors has no effect on *s*-chemokine-mediated phosphorylation of kinases in U343 or A764 cells. However, in CX3CR1-expressing THP-1 cells (compare [Figure 1](#fig1){ref-type="fig"}) CX3CL1 mediated phosphorylation of Akt (stimulation with 1 nM for 20 min) can be inhibited by pre-incubation with PTX. An engineered variant of CX3CL1, the recombinant CX3CR1-antagonist F1 (100 nM, 20 min) induces also signal transduction in primary glioma cells indicating a mechanism different from CX3CR1-binding (and antagonism). Shown are representative Western blots after SDS-PAGE separation of lysates from stimulated U343 or A764 glioma cells stained for pERK 1/2 or pAkt (re-blot to non-phosphorylated kinases, control of equal loading) from 3 independent experiments, compare [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. (**B**) The transcription profile of classical chemokine receptors and chemokine decoy receptors as determined by quantitative RT-PCR shows that the chemokine receptors CXCR3, CXCR4, CXCR6 and CX3CR1 are absent in responsive U343 and A764 and non-responsive LOX cells. However, the atypical chemokine receptor CXCR7 that is known to signal G protein-independently is expressed in responsive cell lines and absent in LOX cells. The chemokine decoy receptors D6 and CCX-CKR are expressed at comparable levels in responsive and non-responsive cells, whereas DARC is absent (n = 3 biological replicates, indicated by diamonds). Additionally, the cytomegalovirus-derived gene US28 that encodes for a putative CX3CR1 receptor could not be detected in these cell lines. The highly glycosylated protein CD44, that may putatively sequester chemokines, was detected at comparable protein levels in U343, A764 and LOX cells (n = 3). (**C**) To investigate the contribution of CXCR7 in *s*-chemokine mediated signaling U343 cells were pre-incubated with the CXCR7-antagonist CCX733 (100 nM, 2 hr) and stimulated with 1 nM of *s*-CXCL16 or *s*-CX3CL1 for 20 min. Controls ± *s*-chemokines were pre-incubated with 0.1% DMSO as solvent controls. The CXCR7-antagonist CCX733 does not impair *s*-chemokine-mediated ERK phosphorylation. Representative Western blots from 3 independent experiments. For biological replicates of western blots please refer to [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.010](10.7554/eLife.10820.010)10.7554/eLife.10820.011Figure 4---figure supplement 1.Biological replicates of western blot experiments with s-chemokines and Pertussis toxin (compare [Figure 4A](#fig4){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.011](10.7554/eLife.10820.011)

These experiments show that soluble chemokines (1) elicit signal transduction and biological effects in cells that do not express their known receptors, (2) the effects are independent from *Pertussis* toxin-sensitive G-proteins and other known chemokine receptors including different decoy receptors, (3) are observed only in cells which express *tm*-chemokines, and (4) occur within a (patho) physiologically relevant concentration range and time frame. Therefore, responsive cells must have either novel receptors, or even likely respond to *s*-chemokines via their *tm*-chemokines.

Transmembrane chemokines bind soluble chemokines {#s2-3}
------------------------------------------------

To identify receptors for *s*-chemokines, we performed binding experiments with labeled peptides ([Figure 5A,B and C](#fig5){ref-type="fig"}). Fluorescent- or biotin-labeled *s*-CXCL16 or *s*-CX3CL1 bound to cells that express their *tm-*chemokine counterparts (as shown by fluorescence microscopy [Figure 5A](#fig5){ref-type="fig"} and FACS analysis [Figure 5B](#fig5){ref-type="fig"}), but not to *tm-*chemokine negative LOX cells. However, when LOX cells were transfected with *tm*-CXCL16 or *tm*-CX3CL1, binding of *s*-CXCL16 or *s*-CX3CL1 was clearly observed. Fluorescent or biotin-labeled control peptides (e.g. lactalbumin conjugates) did not bind to these cells (not shown).10.7554/eLife.10820.012Figure 5.Binding of soluble chemokines to corresponding *tm*-chemokines on cell surfaces.(**A**) Fluorescent soluble chemokines, either labeled directly (cyanine3, Cy3) or indirectly via biotin-label to fluorescent (strept)avidin (Alexa-Fluor 488 or fluorescein-isothiocyanate, FITC), bind to tumor cells expressing *tm*-chemokines (transfected LOX melanoma, or glioma cells, not shown), but not to non-transfected LOX cells as shown by light microscopy. Due to its lipophilic character, the dye Cy3 yields a whiff of background. However, this was also observed with the negative control Cy3-labeled lactalbumin. Chemokine concentrations 2 nM, bars indicate 20 µm. (**B**) FACS analysis confirmed binding signals yielded by fluorescence microscopy. LOX cells transfected with *tm*-CXCL16 were detectable by their binding of biotinylated CXCL16 (2 nM)/Avidin-FITC, whereas mock transfected cells (LOX-pcDNA) were not, and LOX cells transfected with *tm*-CX3CL1 were labeled by biotin-CX3CL1 (2 nM)/Avidin-FITC, in comparison to mock transfected cells. (**C**) A close association between *s-* and *tm-*chemokines is visible by immuno-electron microscopy of *tm-*chemokine-expressing/-transfected cells which were immunolabeled with anti-CXCL16 or CX3CL1 and 15 nm-gold-labeled secondary antibodies and subsequently incubated with 5 nm-gold-labeled (directly or via biotin/streptavidin complex) soluble chemokines (2 nM) before embedding. (**D**) Chemical cross-linking by paraformaldehyde (PFA) shifts *tm*-chemokine bands to higher molecular weights. Isolated membranes of *tm*-chemokine overexpressing LOX cells were incubated over night with 2 nM *s*-chemokines, cross-linked with 1% PFA and subjected to SDS-PAGE separation and subsequent Western blotting using antibodies against the respective chemokine domains of CXCL16 and CX3CL1. All experiments were repeated in 2 independent biological replicates, and representative photographs and immunoblots are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.012](10.7554/eLife.10820.012)

The direct association of *s*- to *tm*-chemokines was also visualized by immuno-electron microscopy ([Figure 5C](#fig5){ref-type="fig"}). For this, *tm*-chemokines were natively stained in glioma cells, *tm*-chemokine transfected and non-transfected LOX melanoma cells with respective antibodies and secondary antibodies labeled with 15 nm gold particles. Subsequently, cells were incubated either with *s*-CXCL16 directly coupled with 5 nm colloidal gold or with biotinylated *s*-CX3CL1 followed by a conjugate of streptavidin and 5 nm gold particles. An association of the different-sized types of colloidal gold particles (exemplarily shown in [Figure 5C](#fig5){ref-type="fig"}) clearly visualizes binding of the *s*-chemokine to cell-anchored *tm*-chemokine.

A direct association of *s*-chemokines to *tm*-chemokines could also be verified by chemical cross-linking ([Figure 5D](#fig5){ref-type="fig"}). Isolated membranes from *tm*-chemokine transfected LOX cells were incubated with their corresponding *s-*chemokine (omitted in controls) and cross-linked by exposure to paraformaldehyde (PFA); then proteins were separated by SDS-PAGE and blots incubated with antibodies to soluble chemokines. Only after cross-linking in the presence of *s*-chemokines a shift of the bands of *tm*-chemokines to higher molecular masses was observed, corresponding roughly to the binding of 1-2 soluble peptides. It should be noted that also soluble chemokines alone polymerize under these conditions with cross-linker (not shown).

These experimental approaches show that *tm*-chemokines bind to their soluble counterparts at nanomolar concentrations and *tm*-chemokines and *s*-chemokines appear in close proximity on the cell surface.

Transmembrane chemokines transduce signals - proof of principle: overexpression and silencing of *tm*-chemokines {#s2-4}
----------------------------------------------------------------------------------------------------------------

To further verify our hypothesis we transfected non-responsive *tm*-chemokine negative LOX cells with expression vectors for *tm*-CXCL16 or *tm-*CX3CL1 and investigated activation of *tm*-chemokine mediated signal transduction ([Figure 6](#fig6){ref-type="fig"}). Upon stimulation with soluble chemokines, transiently (not shown) as well as stably transfected cells showed a time dependent phosphorylation of ERK 1/2 ([Figure 6A](#fig6){ref-type="fig"}), which was not the case in non-transfected cells (compare [Figure 2](#fig2){ref-type="fig"}).10.7554/eLife.10820.013Figure 6.Non-responsive cells can be transformed to be responsive to *s*-chemokine stimulation by transfection with *tm*-chemokines.(**A**) LOX melanoma cells were stably transfected with *tm*-chemokines. Transfection efficiency was controlled by quantitative RT-PCR and immunocytochemistry (n = 3 biological replicates as indicated by diamonds; bars represent 20 µm). Cells were then stimulated with *s*-chemokines (1 nM) and cell lysates analyzed by SDS-PAGE separation and immunoblotting for phosphorylation of ERK 1/2 (re-blots for ERK2 ensure equal loading). Transfected cells responded with ERK 1/2-phosphorylation in contrast to non-transfected cells (compare [Figure 2](#fig2){ref-type="fig"}). (**B**) Stably transfected LOX-cells expressing C-terminally truncated *tm*-chemokine variants lacking the intracellular domain (LOX-ΔCXCL16 and LOX-ΔCX3CL1) cannot be activated by stimulation with *s*-chemokines (1 nM). Thus, the intracellular domain of the *tm*-chemokines seems to be critical for signaling. Successful truncation was proven by co-immunostaining with anti-CXCL16 (extracellular chemokine domain, red) and anti-HA (intracellular tag of the CXCL16-expression vector, green), or band shift in Western blot. To obtain defined bands, proteins were deglycosylated prior to SDS-PAGE. (**C**) Shed chemokine domains found in conditioned media (CM) from overexpressing cells can also mediate activation of *tm*-chemokine transfected LOX cells. Conditioned media were obtained from confluent CXCL16 or CX3CL1 or mock (pcDNA) transfected cells (LOX-CXCL16, LOX-CX3CL1, LOX-pcDNA) and applied to *tm*-chemokine expressing LOX cells for 20 min. SDS-PAGE plus immunoblotting (CXCL16) or ELISA (CX3CL1) proved presence of shed chemokines in the conditioned media used for stimulation. Stimulation with conditioned media containing shed chemokine domains can activate the ERK signaling in *tm*-chemokine transfected cells, but not in pcDNA-transfected or not modified LOX cells. All shown results are representatives from 3 independent experiments, except for the control of successful truncation of *tm*-chemokines in stable clones and experiments with conditioned media that were performed twice; for examples of biological replicates compare [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.013](10.7554/eLife.10820.013)10.7554/eLife.10820.014Figure 6---figure supplement 1.Biological replicates of western blot experiments with transfected LOX melanoma cells (compare [Figure 6](#fig6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.014](10.7554/eLife.10820.014)

As the short intracellular domain of *tm-*chemokines could be involved in this signal transduction, we performed corresponding experiments with C-terminally truncated *tm*-chemokines that lacked the complete intracellular but not the transmembrane domain ([Figure 6B](#fig6){ref-type="fig"}). In fact, this truncation abolished the signal transduction effects observed with the full-length *tm*-chemokines.

Next, to exclude experimental artifacts from recombinant *s*-chemokines, we wanted to verify if the naturally occurring *s*-chemokines, which are released by proteolytic cleavage from their *tm*-forms, could also elicit *tm*-chemokine-signaling. Since transfected cells should release *s*-chemokines by shedding over time, we tested first their occurrence in conditioned medium, and then assayed if conditioned, *s*-chemokine-containing media could induce signals in overexpressing cells that were washed prior to experiments. In fact, 24 hr- or 48 hr-conditioned media of *tm*-chemokine-transfected cells, but not of vector-transfected cells, contained considerable amounts of corresponding *s*-chemokines as detected by Western blot or ELISA ([Figure 6C](#fig6){ref-type="fig"}). As expected, conditioned media from transfected, but not from control cells, induced ERK 1/2 phosphorylation; again non- or control-transfected LOX cells yielded no signal transduction ([Figure 6D](#fig6){ref-type="fig"}).

Regarding biological effects of *s-*chemokines in *tm*-chemokine-transfected LOX cells we could observe a rescue from Camptothecin-induced cell death events. As shown by immunocytochemistry and Western blot, stimulation of *tm*-CXCL16-transfected LOX cells with *s-*CXCL16 and *tm*-CX3CL1-transfected LOX cells with *s*-CX3CL1 significantly reduced the amount of the cleaved Poly (ADP-Ribose) Polymerase (PARP), whereas mock-transfected LOX cells were not rescued ([Figure 7](#fig7){ref-type="fig"}).10.7554/eLife.10820.015Figure 7.Stimulation with *s*-chemokines can mediate rescue from chemically-induced cell death in *tm*-chemokine-transfected LOX melanoma cells.LOX melanoma cells stably expressing *tm*-CXCL16 or *tm*-CX3CL1 (or mock transfected LOX cells) were treated for 18 hr with 0.1 µg/ml Camptothecin (inhibitor of topoisomerase I) to induce cell death. Simultaneous stimulation of *tm*-CXCL16-LOX with 1 nM *s*-CXCL16 or *tm*-CX3CL1-LOX with 1 nM *s*-CX3CL1 significantly reduced cell death as indicated by reduced cleavage of poly(ADP ribose) polymerase (PARP) (shown by Western blot after SDS-PAGE, n = 2 biological replicates; or immunocytochemistry, n = 3-4 biological replicates, indicated by diamonds). In contrast, mock-transfected (pcDNA) LOX cells did not show reduced signals of cleaved PARP when stimulated with *s*-CXCL16 or *s*-CX3CL1. Bars represent 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.015](10.7554/eLife.10820.015)

As contrary approach to overexpression in non-responsive, *tm*-chemokine negative cells, silencing of *tm*-chemokines in responsible cells can further prove our concept. Therefore, we reduced *tm*-chemokines in responsive receptor-negative glioma cell lines and primary cultures from surgical samples by siRNA and stimulated with the corresponding soluble chemokines ([Figure 8](#fig8){ref-type="fig"}). By siRNA silencing, *tm*-chemokine transcript amounts were reduced up to 24-59% of controls transfected with unspecific control siRNAs. The *s*-chemokine-mediated ERK-phosphorylation could be observed in control siRNA-treated glioma cell lines and primary cultures but was clearly reduced in *tm*-chemokine silenced cells.10.7554/eLife.10820.016Figure 8.Silencing of *tm*-chemokine expression abolishes the s-chemokine mediated activation in responsive glioma cell lines and primary cultures.Cell lines and primary cells were transfected with CXCL16 or CX3CL1 specific RNAi (or non-specific control RNAi), left for recovery for 36 hr and stimulated with 1nM CXCL16 or CX3CL1 for 15 min. Samples were analyzed by SDS-PAGE separation and immunoblotting for phosphorylated ERK 1/2, and re-probed for ERK 2 to ensure equal loading. Silencing efficiency and basic transcription level were confirmed by quantitative RT-PCR (right panel). In *tm*-chemokine silenced cultures, no activation can be observed by incubation with the respective *s*-chemokine. Experiments with T98G were repeated in 2 independent biological replicates, shown primary cultures are representative examples from 2 different patient's primary cultures (compare [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.016](10.7554/eLife.10820.016)10.7554/eLife.10820.017Figure 8---figure supplement 1.Biological replicates of western blot experiments from siRNA knockdown in T98G glioma cells (compare [Figure 8](#fig8){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.017](10.7554/eLife.10820.017)

Antibodies specific for the ligand portion are known to activate signaling of transmembrane ligands such as of *tm*-TNF-α([@bib6]probably as they can mediate the required di/multimerization. To find out, whether antibodies against the chemokine domains of CXCL16 or CX3CL1 can also induce signaling of the *tm*-chemokines, we stimulated stably transfected *tm*-CXCL16 or *tm*-CX3CL1 LOX cells with 0.1 µg/ml of the respective antibody ([Figure 9A](#fig9){ref-type="fig"}); IgG from the same species and mock-transfected cells served as controls. In fact, specific antibodies, but not controls induced ERK1/2 phosphorylation in *tm-*chemokine expressing cells. To test if the activation potential depends on di-/oligomerization of the *tm*-chemokines, we compared the efficiency of complete to monovalent antibodies. However, monovalent F(ab) fragments of the same antibodies generated by papain digestion and purification did not produce any effects in transfected cells ([Figure 9B](#fig9){ref-type="fig"}). These experiments show that antibodies like soluble ligands induce signal transduction through *tm*-chemokines, and this process seems to depend on di/oligomerization of the *tm-*chemokines.10.7554/eLife.10820.018Figure 9.Signal transduction in *tm*-chemokine expressing LOX cells upon stimulation with specific antibodies (0.1 µg/ml), but not monovalent F(ab) fragments.(**A**) As shown by Western blot after SDS-PAGE, stimulation of *tm*-CXCL16 or *tm*-CX3CL1 transfected LOX cells for 20 min with antibodies against the corresponding chemokine domains (0.1 µg/ml), yields a phosphorylation signal for ERK1/2. Non-specific control IgG could not elicit signaling, nor could specific antibodies activate mock-transfected (LOX-pcDNA) cells (positive stimulation control: 2 nM FGF-2, n = 2-3 biological replicates, for corresponding effects in glioma cells compare [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). (**B**) In contrast to the intact specific antibodies, monovalent F(ab) fragments (0.1 µg/ml) obtained by papain digestion and clean-up of these fragments failed to mediate ERK1/2 phosphorylation as demonstrated by Western blot and immunocytochemistry (FGF-2 serves as positive control, n = 3 biological replicates, Bars represent 50 µm).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.018](10.7554/eLife.10820.018)10.7554/eLife.10820.019Figure 9---figure supplement 1.Biological replicates of western blot experiments of stimulations with chemokine-specific antibodies (compare [Figure 9](#fig9){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.10820.019](10.7554/eLife.10820.019)

In summary, transfection as well as silencing experiments evidence that transmembrane chemokines transduce signals when stimulated with nanomolar concentrations of corresponding soluble counterparts exerting also biological effects as exemplarily shown by rescue from apoptosis. Thereby, signaling is elicited by recombinant peptides (chemokine domain) or soluble chemokines produced by transfected cells themselves. Furthermore, the intracellular C-terminal domains of *tm*-chemokines are required for these effects. Furthermore, specific chemokine domain-directed antibodies, but not monovalent fragments induce signaling emphasizing the necessity of dimerization of the *tm*-chemokines to induce signaling. Thus, *tm*-chemokines do not only bind *s*-chemokines, but also induce a signal transduction and further biological effects specifically.

Discussion {#s3}
==========

Reverse signaling of transmembrane ligands together with classical receptor signaling is an important mode of bidirectional signaling, both in the nervous and immune systems. We here provide evidence for a novel form of auto- and paracrine signaling of transmembrane ligands produced by their shed, soluble ligands -- a process that we term 'inverse signaling'. Whereas reverse signaling requires the binding of the transmembrane ligand to its classical membrane-bound or soluble receptor, the inverse signaling depends on binding of the soluble ligand to its transmembrane counterpart.

This binding of the soluble forms of the chemokines CXCL16 and CX3CL1 to their transmembrane counterparts - as a prerequisite for inverse signaling - was verified by FACS analysis, morphological assays at the light- and electron-microscopic levels and chemical cross-linking experiments. Similarly, di- and multimerization of the chemokine domain of CX3CL1 had already earlier been shown by X-ray crystal structure ([@bib20]), and is also known for some other (soluble) chemokines.

Next to the ability to bind to *tm-*chemokines, *s*-chemokines may also elicit intracellular signals. This could be clearly shown in primary glioblastoma cells and corresponding cell lines. After transfection with *tm-*chemokine expression vectors, previously non-responsive cells may also exert inverse signaling upon stimulation with *s-*chemokines. Opposite to overexpression, silencing of *tm*-chemokines reduces signaling induced by *s*-chemokine stimulation. Consequently, by two different approaches (overexpression and silencing) signal transduction of the *s*-chemokines was shown to depend on the expression level of transmembrane CXCL16 or CX3CL1 in the responsive cell line. Apart from recombinant peptides, also the naturally shed soluble ligands as contained in conditioned media were able to induce inverse signaling and, as a sign of specificity, antibodies raised against the chemokine domain of CXCL16 or CX3CL1 yielded comparable signals. This activation of *tm*-chemokine signaling by intact antibodies but not by corresponding monovalent F(ab) fragments supports a putative necessity of di/oligomerization of the *tm*-chemokines for the inverse signaling. And indeed, a clustering/bundle formation of transmembrane CX3CL1 has been observed in transfected and primary cells by bioluminescence resonance energy transfer (BRET) and homogeneous time-resolved fluorescence (HTRF; [@bib19]; [@bib34]).

However, it is not unlikely, that inverse signaling may require a co-receptor supporting the *tm*-chemokines. Some other classical chemokine receptors evaluated are either absent, or can be excluded. For example, inverse signaling is insensitive to *Pertussis* toxin, an inhibitor of classical chemokine receptor signaling via G~i/o~-proteins, and is not affected by inhibition of CXCR7, a non-canonical chemokine receptor signaling via arrestin. However, putative co-receptors (and also intracellular binding partners) need further investigation.

Signaling domains of the intracellular tails of transmembrane ligands seem to be critical for the signal transduction in reverse signaling, and thus also may transduce inverse signaling. For example, TNF-α, FasL and other members of the TNF family, contain S/TXXS/T sequences and proline-rich domains (FasL) that can bind adaptor proteins and thereby transduce signals ([@bib25]; [@bib46]; [@bib6]; [@bib43]; [@bib2]; [@bib5]). In contrast, ephrins and semaphorins signal through PDZ-binding motifs and also proline-rich domains ([@bib26]; [@bib51]; [@bib5]). As shown by transfection/stimulation experiments with C-terminally-truncated *tm*-chemokines, the intact intracellular domains are also essential for the inverse signaling. Identification of the exact binding sites for kinases/adaptor proteins are ongoing and beyond the scope of this investigation. Potential activation sites include cytoplasmic SXXS-sequences (comparable to those of the TNF family) and additionally SH2-binding sites (YXPV/R). In CX3CL1, both sites are highly conserved from monotremes through marsupials to highly developed mammals; in the case of CXCL16, they are found -- as far as known - in primates and only same mammals ([Table 1](#tbl1){ref-type="table"}). Thus, the transfer to a rodent *in vivo* model has to be carefully designed. Of note, the reverse signaling of TNF-α has long been described ([@bib7]; [@bib27]; [@bib6]; [@bib40]), but exact mechanisms of further downstream signaling are not yet known. Apparently, there may be an analogy of transmembrane ligand signaling between ligands of the TNF family and transmembrane chemokines that might be elucidated in future investigations.10.7554/eLife.10820.020Table 1.Sequences of putative intracellular domains from transmembrane chemokines.**DOI:** [http://dx.doi.org/10.7554/eLife.10820.020](10.7554/eLife.10820.020) **CX3CL1***Homo sapiens* (Human)-QSLQGCPRKMAGEMAEGLR*YIPR*[SCGS]{.ul}NSYVLVPV*Nomascus leucogenys* (Northern white-cheeked gibbon)-QSLQGCPRKMAGEMAEGLR*YIPR*[SCGS]{.ul}NSYVLVPV*Macaca mulatta* (Rhesus macaque)-QSLQGCP RKMAGEMVEGLR*YIPR*[SCGS]{.ul} NSYVLVPV*Bos taurus* (Bovine)-QRLQSCPHKMVGDVVEGIC*YVPR*[SCGS]{.ul}NSYVLVPV*Canis familiaris* (Dog)-YQSLQGCSR KMAGDMVEGLR*YVPR*[SCGS]{.ul}N SYVLVPV*Oryctolagus cuniculus *(Rabbit)-Q SLQGCPRKMAGEMVEGLR*YV PRSCGA*NSYVLVPV*Cavia porcellus *(Guinea pig)-QSLQGCPRK MAGEMVEGLR*YVPR*[SCGS]{.ul}NSYVLVPV*Rattus norwegicus* (Rat)-QS LQGCPRKMAG EMVEGLR*YVP R*[SCGS]{.ul}NSYVLVPV*Mus musculus* (Mouse)-QSLQGCPRKM AGEMVEGLR*YVPR*[SCGS]{.ul}NSYVLVPV*Monodelphis domestica *(Gray short-tailed opossum)-QSLQSCPRRMAGEVVEGLR*YIPR*[SCGS]{.ul}NSYVLVPV*Sarcophilus harrisii *(Tasman devil)-QSLQSCPRRMAGEVVEGLR*YIPR*[SCGS]{.ul}NSYVLVPV*Ornithorhynchus anatinus *(Duckbill platypus)-QSLQSCPRRMAGEVVEGLR*YIPR*[SCGS]{.ul}NSYVLVPV**CXCL16***Homo sapiens* (Human)-CKRRRGQ[SPQS]{.ul}SPD PVH*YIPV*AP DSNT*Gorilla gorilla gorilla *(Lowland gorilla)-CKRRRGQ[SPQS]{.ul}SPGLPVH*YIPV*APDSNT*Nomascus leucogenys *(Northern white-cheeked gibbon)-CKR RRGQ[SPQS]{.ul}SPDLQFH*YIPV*A PDSNT*Macaca mulatta *(Rhesus macaque)-CKRRGQ[SPQS]{.ul}SPDLQLH*YIPV*ASDSNT*Sus scrofa* (Pig)-CKKRQEQSRQYPPDPQLH*YVPV*ASNINT*Loxodonta africana *(African elephant)-CKRRREQSRLYYPDLQFH*YKPV*A PDS*Bos taurus* (Bovine)-C KRRKNQLLQHPPDLAASLYT CSRRTRAENGTL*Equus caballus* (Horse)-CKKREKTLRPSPDLQAHYERVAPD*Canis familiaris* (Dog)-CKRREQSLQHPPDLQLH*YTPV*A*SDS*NV*Oryctolagus cuniculus *(Rabbit)-CKRRRGRSPKYSSGKP*Rattus norwegicus* (Rat)-CNRRVTRQ*SSSG*LQLC*YTPV* EPRPQGL*Mus musculus* (Mouse)-CNRRATQQNSAGLQLW*YTPV*EPRP*Myotis lucifugus *(Little brown bat)-CKRRSKQSPQYSPDLQLQCIPVASYSNS*Ornithorhynchus anatinus *(Duckbill platypus)-CRRRGAPRNEMLYPQRPKGTSITVQANSPT[^3][^4][^5][^6][^7]

Concerning the biological consequences of 'non-classical' signaling, reverse signaling in the case of TNF members mediates co-stimulation, direct stimulation, desensitization and migration yielding a fine-tuning in adaptive immunity and a regulatory feedback in innate immunity ([@bib6]; [@bib43]). Reverse signaling of ephrins triggers cell adhesion or differentiation, in particular in the nervous system, spine and synapse formation, but also in bone modeling ([@bib26]; [@bib31]; [@bib50]), whereas reverse signaling of semaphorins similarly regulates cell guiding and repulsion, especially in the nervous system ([@bib50]). As far as we know, inverse signaling of transmembrane chemokines appears to induce mainly autocrine stimulatory and stabilizing effects like increased proliferation and anti-apoptosis. These tumor cell protective effects could also be confirmed in transfection experiments enabling a direct comparison of the chemokine effects in *tm-*chemokine expressing versus not-expressing cells of the same cell line. To our knowledge, these effects seem to depend on the *tm*-chemokine expression level rather than the (tumor) cell type. Obviously, tumors would clearly profit from such positive feedback. The importance of autocrine loops in many types of tumors becomes obvious regarding for example growth factors like epidermal (EGF) or platelet-derived (PDGF) growth factors. However, also in inflammation or under non-pathological conditions in tissue development these stabilizing autocrine loops may play important roles.

The expression of transmembrane chemokines can be induced by pro-inflammatory cytokines like TNF-α, IFN-γ and interleukin-1β, e.g. in fibroblasts and endothelial cells ([@bib10]; [@bib1]; [@bib23]) regulating their role in inflammatory (trans-) migration processes. The release of the chemokine domain is mediated by the cell surface proteases ADAM10 and ADAM17 in a constitutive (mainly ADAM10) or cytokine-induced manner ([@bib1]; [@bib28]). ADAM17 was initially discovered as TNF-α-converting enzyme (TACE) liberating soluble cytokine from the transmembrane form. Later, other ADAMs were identified as similar 'sheddases', but they also cleave receptors, adhesion molecules and intracellular signaling molecules ([@bib36]). ADAMs are supposed to terminate reverse signaling by cleaving transmembrane ligands of the TNF family bound to their receptors ([@bib43]). In case of ephrin-A, ADAM10 is constitutively associated with the EphA receptor that clusters and is activated upon ligand binding; this positions the proteinase domain for effective ephrin-A5 cleavage and the cleavage occurs in *trans*, with ADAM10 and its substrate being on the membranes of opposing cells ([@bib24]). This mechanism ensures that only Eph-bound ephrins are recognized and cleaved. A corresponding regulatory role of ADAMs as for reverse can also be supposed for inverse signaling. Since different physiological and pathophysiological mediators or therapeutics tightly regulate ADAM activities ([@bib37]), inverse signaling should also be modulated in diverse ways in health and disease. However, this question may only be satisfactory addressed in carefully designed future *in vivo* experiments.

A potential regulation of the *tm*-chemokine signaling may also be expected by the interplay of 'inverse' and 'classical' signaling, since both, classical receptors and transmembrane chemokines compete for the same soluble ligand. For example in an inflammatory context, binding of *s-*chemokines to *tm-*counterparts might reduce the recruitment of immune cells expressing the classical receptors, and vice versa might a massive infiltration of *s-*chemokine binding immune cells reduce the effects of inverse signaling. Moreover, it can be hypothesized that inverse signaling interacts with signaling of classical receptors, e.g. by adapter proteins. Thus, the observed novel mechanism adds to the understanding of the complex chemokine system.

Conclusions {#s3-1}
-----------

Inverse signaling is an autocrine feedback and fine-tuning systems in the communication between cells. Here, soluble ligands that are shed from their transmembrane counterparts induce signals through binding to the transmembrane ligands. Though this was shown here for transmembrane chemokines for the first time, a broader distribution, e.g. in signaling of other transmembrane ligands, and further biological effects have to be further evaluated under normal and pathological conditions *in vitro* and in suitable *in vivo* models.

Materials and methods {#s4}
=====================

Peptides and inhibitors {#s4-1}
-----------------------

Recombinant human chemokines and growth factors were from PeproTech (Hamburg, Germany), R&D-Systems (Wiesbaden, Germany), or Immunotools (Friesoythe, Germany), *Pertussis* toxin (inhibits G protein-signaling) was from Calbiochem (Merck, Darmstadt, Germany) or Sigma-Aldrich (Munich, Germany). The CX3CR1-antagonist F1, an engineered N-terminally modified recombinant CX3CL1 analogue that binds to CX3CR1 but does not induce signaling, was a kind gift from Prof. Dr. Philippe Deterre, Laboratoire Immunité et Infection, INSERM, Faculté de Médcine Pitié-Salpêtrière, Paris, France ([@bib19]). The synthetic CXCR7-antagonist CCX733 was a kind gift from Dr. Mark E.T. Penfold and Prof. Dr. Thomas J. Schall (ChemoCentryx Inc, Mountain View, CA).

Cell cultures {#s4-2}
-------------

Human glioma cell lines A172 ([@bib12]; ATCC® CRL-1620; ECACC No. 88062428) and T98G ([@bib42]; ATCC CRL-1690; ECACC No. 92090213) glioma cells were purchased from LGC Standards GmbH (Wesel, Germany), U343-MG ([@bib47]) and U118-MG ([@bib35]; ATCC HTB-15; identical with the glioma cell line U138; U118 was only used for expression data) were obtained from "Deutsches Krebsforschungszentrum" ("Tumorbank"; Heidelberg, Germany). Primary glioma cells and the cell line A764 were generated by dissociation from a solid tumor and cultivation (cell line: repeated subcultivation) in Dulbecco\'s modified Eagle\'s medium (DMEM; PAN Biotech, Aidenbach, Germany) plus 10% fetal calf serum, FCS. Glioma samples were obtained in accordance with the Helsinki Declaration of 1975 with approval of the ethics committee of the University of Kiel, Germany (file reference: D 442/11 and D 427/15) and after written consent of donors. The mamma carcinoma cell line MCF-7 ([@bib41]; ATCC HTB-22; ECACC No. 86012803) cells and the monocytic cancer cell line THP-1 ([@bib45]; ATCC TIM-202; ECACC No. 88081201) were obtained from Cell Line Service (Eppelheim, Germany). The LOX melanoma cell line (established by [@bib8]; and cited by [@bib44]), the HT29 colon carcinoma cell line (described by [@bib9]; and obtained from European Cell Culture Collection, Porton Down, Salisbury, UK; ATCC HTB-38; ECACC No. 91072201), the SH-SY5Y neuroblastoma cell line (established by [@bib4]; and provided by Prof. Dr. Hildebrandt, Institute of Cellular Chemistry, Medical School Hannover, Germany; ATCC CRL-2266; ECACC No. 94030304), and the OH3 small cell lung cancer cell line (established by [@bib13] and cited by [@bib39]) were gifts from Prof. Dr. Udo Schumacher, Dept. of Anatomy, University of Hamburg, Germany. These cell lines were cultivated in RPMI plus 10% FCS. Preparation of T cells has been described previously ([@bib28]). HUVEC cells were obtained by Promocell (Heidelberg, Germany), cultivated in Endothelial growth medium (Promocell) and used up to passage 5. All cell lines were kept in a master stock -- working stock routine to exclude cross-contaminations and monthly checked for mycoplasma contamination by DAPI staining or PCR (Venor GeM Mycoplasma Detection Kit, Minerva Biolabs, Berlin, Germany). All cell lines were free of mycoplasma contamination.

Stimulation of cells {#s4-3}
--------------------

For signaling experiments, cells were seeded on 25 cm^2^ culture flasks, cultivated in medium overnight, washed serum- and chemokine-free (2x, with 1 hr intervals) and stimulated in DMEM plus 0.5% fatty acid-free bovine serum albumin, BSA (Sigma-Aldrich), or RPMI plus 5--10% FCS. Chemokines/growth factors, antibodies or inhibitors were added from stocks in phosphate buffered saline (PBS), or in dimethylsulfoxide (DMSO); in this cases controls were run with a corresponding DMSO concentration (maximum 0.1% ). For *Pertussis* toxin experiments, cells were pre-incubated with the inhibitor overnight, and the concentration (200 ng/ml) maintained during the stimulations. For inhibition of the chemokine receptor CXCR7, the CXCR7-specific antagonist CCX733 was added 2 hr prior to the stimulation and the concentration (100 nM) maintained during the chemokine stimulation. To prepare monovalent F(ab) fragments, 5 µg antibody specific for CXCL16 or CX3CL1 (PeproTech) or control IgG (DAKO, Glostrup, Denmark) were incubated with 800 µg immobilized papain (agarose resins, Pierce/Life technologies, Darmstadt, Germany) for 6 hr at 37°C under gentle shaking (350 rpm). After centrifugation for 3 min at 5000 ×g, 20 µl of protein-A agarose (Santa Cruz, Santa Cruz, CA) were added to the supernatant and incubated for 1.5 hr at 4°C and shaking (350 rpm). After another centrifugation step (1000 ×g, 5 min), the supernatant was cleaned-up by spinning through a G25-Sephadex column (800 ×g, 2 min; Amersham/GE Healthcare). Cells were stimulated with 0.1 µg/ml F(ab) fragment for 20 min.

Plasmids, mutations and transfection experiments {#s4-4}
------------------------------------------------

Expression vectors for CXCL16-HA (with a hemagglutinin HA tag) and CX3CL1 were established as previously described ([@bib1]) in a pcDNA3.1 backbone (Invitrogen, Karlsruhe, Germany), and pcDNA 3.1 was used for control transfections. Transfection was performed with TurboFect (Fermentas, St. Leon-Rot, Germany) in serum-free DMEM without antibiotics using 4 µg of the respective expression vectors with pcDNA3.1 backbone and 4 µl TurboFect in a total volume of 1 ml. After 6 hr, cells were rinsed and normal growth medium (RPMI + 10% FCS) was added. Successful transfection was controlled by immunocytochemistry and/or qRT-PCR. Stable clones were generated by selection with 0.75 mg/ml G418 (Calbiochem), and colonies were picked after 10--20 days, amplified and checked for expression by quantitative RT-PCR and immunocytochemistry. Site directed mutagenesis was performed with the QuikChange Site-Directed Mutagenesis Kit following the manufacturer´s advice (Agilent Technologies, Böblingen, Germany). The complementary primer pairs were designed to generate a double stop codon following the transmembrane domain (MWG-Biotech, AG Ebersberg, Germany; CXCL16: 5'-ctttcctatgtgctg**tgatag**aggaggagggggcag-3', CX3CL1: 5'-tggccatgttcacctac**tagtaa**ctccagggctgccctcg-3') yielding expression of C-terminally truncated *tm-*chemokines, respectively. Successful mutations were verified by sequencing of the plasmids (GATC Biotech AG, Koblenz, Germany). Surface expression of overexpressed native or truncated *tm*-chemokines was verified by immunocytochemistry. Successful C-terminal truncation of CXCL16 was proven by immunocytochemistry (see below) using antibodies against the extracellular chemokine of CXCL16 (PeproTech, \#500-P200) and the HA-tag of CXCL16 (Cell signaling, \#2367, clone 6E2). Successful C-terminal truncation of CX3CL1 was proven by band shift in western blot (see below) with an antibody against the extracellular domain of CX3CL1 (Pepro Tech, \#500-P98). Therefore, cell membranes were isolated^17^ and - to obtain defined bands - subjected to N-deglycosylation by PNGase F (New England Biolabs, Ipswich, MA) following the manufacturer's instructions. Western blot was performed as described below.

Quantitative RT-PCR {#s4-5}
-------------------

RNA was isolated with the TRIZOL reagent, digested by DNase, cDNA synthesized and real time RT-PCR was performed ([@bib28]) using TaqMan primer probes (Applied Biosystems, Foster City, CA, USA): *hGAPDH* (Hs99999905_m1), *hCXCL16 (Hs00222859_m1), hCXCR6 (Hs00174843_m1), hCX3CL1 (Hs00171086_m1), hCX3CR1 (Hs00365842_m1), hCXCR3 (Hs00171041_m1), hCXCR4 (Hs00607978_s1), hCXCR7 (Hs00664172_s1), hD6 (Hs01907876_s1), hDARC (Hs01011079_s1), hCCX-CKR (Hs00664347_s1).* A Custom TaqMan primer probe set was used for the detection of the cytomegalovirus gene encoding protein US28: US28F-5′- CGGCAACTTCTTGGTGATCTTC-3′, US28R-5′- CATCGCCGGAGCATTGA-3′, FAM- CCATCACCTGGCGACGTCGGA-MGB ([@bib29]). Cycles of threshold (C~T~) were determined with an ABI PRISM 7000 Sequence detection system. ∆C~T~ values = C~T~Gene of interest - C~T~GAPDH (glyceraldehyde-3-phosphate dehydrogenase, housekeeping gene). A ∆C~T~ value of 3.33 corresponds to one magnitude lower gene expression compared to GAPDH. Biologically independent replicates of cell lines and stable clones were obtained from three independent cultures, e.g. from different passages. Diamonds in the respective graphs indicate biological replicates. Expression data shown for primary cultures and silencing experiments are directly matched to the corresponding stimulation experiments.

Western blotting {#s4-6}
----------------

Western blotting was performed as described ([@bib14]). Briefly, cell lysates (5 µg per lane) were separated by electrophoresis using 10% acrylamide gels, transferred to polyvinylidene fluoride (PVDF) membranes by blotting and incubated with primary antibodies (rabbit anti-phospho-ERK1/2, 1:500, and rabbit anti- phospho-Akt, 1:500, Cell Signaling Technology, Danvers, MA, \# 9101 and \#406, and mouse-anti-CD44 MEM-85, 1:400, Abcam, Cambridge, UK, ab2212) and afterwards horseradish-peroxidase labeled secondary antibody (goat anti-rabbit, 1:30,000; or goat anti-mouse, 1:30,000, Santa Cruz, Santa Cruz, CA) followed by chemo-luminescence detection (GE Healthcare, Munich, Germany or Millipore, Darmstadt, Germany). To ensure equal loading amounts membranes were reactivated with methanol, stripped with ReBlot Plus Strong Antibody Strip Solution (Millipore) and re-probed with antibodies against the non-phosphorylated proteins (rabbit anti-ERK2, 1:250; Millipore \#05-157 or rabbit anti-Akt, 1:500, Cell Signaling).

Conditioned media {#s4-7}
-----------------

To obtain conditioned media for stimulation experiments LOX melanoma cells overexpressing CXCL16 or CX3CL1 (or mock transfected control LOX cells) were washed once with PBS and were incubated for 24 hr (CX3CL1)/48 hr (CXCL16) with 3.5 ml DMEM containing 0.5% BSA. The supernatants were centrifuged (5 min, 1500 rpm) to remove cell debris. Soluble CX3CL1 was quantified by ELISA following the manufacturer´s advice (R&D Systems). For CXCL16-quantification, 75 µl of the conditioned media were mixed with 25 µl of SDS-sample-buffer (100 mg/ml SDS, 0.25 M dithiothreitol, 50% glycerin, 0.3 M Tris/HCl pH 6.8 + 0.3% SDS), incubated at 97°C for 10 min and 20 µl were loaded on a 15% acrylamide gel and separated by electrophoresis. Western blotting was performed as described above (rabbit anti-CXCL16, 1:500; PeproTech). Matched experiments of *s*-chemokine determinations and stimulations were performed two times independently; representatives are shown.

Immunocytochemistry, binding experiments and electron microscopy {#s4-8}
----------------------------------------------------------------

For light microscopy, cells grown on poly-D-lysine-coated cover slips were fixed with ice-cold acetone/methanol (1:1), incubated with antibodies and nuclei counterstained with 4´,6-diamino-2-phenylindole (DAPI) as described ([@bib14]). Primary antibodies were: anti-CXCL16 and anti-CX3CL1 (both from rabbit, diluted 1:100 in PBS, PeproTech), and anti-HA (mouse, 1:100; Cell signaling); secondary antibodies: donkey anti-rabbit or donkey anti-mouse IgG conjugated with Alexa Fluor 488 or Alexa 555 (1:800, Invitrogen/ Life technologies). For binding experiments with CXCL16, cells were incubated with directly Cy3-labeled CXCL16 or lactalbumin (negative control with comparable molecular weight) at 4°C for 60 min in the dark, washed, fixed and nuclei counterstained with DAPI. Labeling was performed using monoreactive Cy3 NHS ester (GE Healthcare) following the manufacturer's instructions. Briefly, 2 µg protein was incubated with a four-fold excess of reactive dye in 0.2 M NaHCO~3~, pH 8.4 (total reaction volume 90 µl). The reaction was stopped by addition of 1 µl 0.1 M Tris, pH 7.3. For binding experiments with CX3CL1, cells were incubated with biotinylated CX3CL1 or the control peptide (Fluorokine, R&D Systems) at 4°C for 60 min, washed, incubated with Alexa Fluor 488 streptavidin (Invitrogen/ Life technologies), washed again, fixed and nuclei were counterstained with DAPI. For flow cytometry analyses, cells were detached using 0,5 mM EDTA, stained with the CX3CL1 Fluorokine Assay following the manufacturer's advice. For CXCL16 experiments, recombinant CXCL16 (Pepro Tech) was biotinylated with the One-step antibody biotinylation kit (Miltenyi Biotech, Auburn, CA) and used (instead of biotinylated CX3CL1) with the Fluorokine kit components. Cells were analyzed using a FACSCanto System (BD Bioscience, Heidelberg, Germany). For electron microscopy, cells seeded on coated cover slips were pre-incubated in serum free DMEM (+0.5% fatty-acid free BSA) for 30 min at 37°C, then slowly cooled down (30 min room temperature, 15 min 8°C, 15 min 4°C). All following incubation and washing steps were performed at 4°C and with pre-chilled buffers and media. Cells were briefly washed (3x) with 145 mM NaCl, 5 mM KCl, 1.8 mM CaCl~2~, 1 mM MgCl~2~, 20 mM Hepes, pH 7.4, and incubated with the primary antibody (anti-CXCL16 or anti-CX3CL1, see above, 1:100) for 60 min, washed again and incubated with the secondary antibody (goat anti-rabbit with adsorbed 15 nm gold (Au) particles, diluted 1:40, British BioCell International, Cardiff, UK) for 60 min. Cover slips were washed again and incubated with 3 µg/ml either recombinant CXCL16 with adsorbed 5 nm gold particles or with biotinylated recombinant CX3CL1 (R&D Systems) and subsequent with streptavidin adsorbed to 5 nm gold particles (British BioCell International). Cells were fixed with 4% glutaraldehyde/ 0.5% paraformaldehyde, embedded in Araldite, sectioned and viewed on a Zeiss EM 900 electron microscope. Samples were only slightly contrasted (45 min 2% osmium tetroxide before embedding and 5 min uranyl acetate (saturated) after sectioning), as strong contrasting (e.g. with lead citrate) would not allow for clear detection of gold particles. Thus, contrast of electron micrographs was digitally enhanced. Images shown are representative views of 3 (ICC) or 2 (FACS, EM) independent stimulations/ immunostainings.

Cross-linking {#s4-9}
-------------

After membrane isolation ([@bib17]) proteins were dissolved in 0.2 M triethanolamine-hydrochloride (pH 8.0), and 1.5 mg membrane-protein was incubated with 2 nM recombinant *s-*chemokine (PeproTech) over night at 4°C under slow shaking conditions. Subsequently 1% paraformaldehyde was added for cross-linking and incubated for 1 hr at room temperature. The reaction was stopped with addition of 1 M Tris (pH 8.3) and incubation for 15 min. Electrophoresis and Western blotting was performed as described above (rabbit anti-CXCL16 /anti-CX3CL1, 1:500; PeproTech), representatives from 2 independent experiments, respectively, are shown.

siRNA silencing {#s4-10}
---------------

After cultivation of glioma cells (primary cultures and established cell lines) in DMEM plus 10% FCS in 6-well dishes (150,000 cells /well) for 24 hr, cells were transfected with siCXCL16 RNA or siCX3CL1 RNA (CXCL16 siRNA ID: s33808; CX3CL1 siRNA ID: s12630; both 50 pmol/well; Life technologies) dissolved in a mixture of Opti-MEM Medium and lipofectamine (Life technologies) for 6 hr. In parallel a transfection with silencer select negative control siRNA (Life technologies) was performed under same conditions. After transfection cell culture medium was changed and glioma cells were cultured for another 24 hr in DMEM plus 10% FCS. Then, cells were washed 20 min for three times with DMEM plus 0.5% FCS and afterwards stimulated for 15 min with recombinant CXCL16 or CX3CL1 (10 nM; PeproTech) dissolved in DMEM plus 0.5% FCS. Cells were lysed and applied for Western Blot experiments as described above, representative data from 2 independent stimulations of cell lines, and 2 different patients' derived primary cultures are shown.

Migration, proliferation and anti-apoptosis assays {#s4-11}
--------------------------------------------------

Migration was analyzed in wound healing assays (scratch assay, [@bib16]). Briefly, 200,000 cells/well were seeded on 6-well dishes, grown to confluence, scratched with a pipet tip, washed and supplemented with stimuli, media with 10% fetal calf serum served as positive control. In each experiment, three scratch regions were photographed at 0 and 24 hr. Scratch areas were measured and differences between 24 and 0 hr were determined (yielding the settled area). Stimuli were normalized to non-stimulated controls. To measure proliferation, 5000 cells/well were seeded on 96 well plates and grown for 24 hr. Then media were changed to DMEM containing 1% BSA (plus respective stimuli or 10% fetal calf serum as positive control). After 24 hr incubation, proliferation was determined by the measurement of tetrazolium salt WST-1 cleavage (Roche, Mannheim, Germany) and normalized to non-stimulated control (3 individual wells for each stimulus). To investigate reduction of apoptosis, 300.000 cells were seeded in 25 mm^2^ culture flasks and cultured for 2 days to reach confluency of 80%. Apoptosis was induced by addition of Temozolomide (400 µg/ml, Sigma-Aldrich) or 0.1 µg/ml Camptothecin applied in a stock solution in DMSO; the final solvent concentration of 2% (Temozolomide), 0.1% (Camptothecin) or 0.1 µM Staurosporine in cultures was also used in controls. After 48 hr, caspase-3/7 activity in glioma cells was measured with 40 µM Ac-DEVD-AMC (AMC, 7-amino-4-methylcoumarine; Bachem, Bubendorf, Switzerland) after lysis in 100 mM NaCl, 0.1% CHAPS, 10 mM dithiothreitol, 1 mM EDTA, 10% glycerol, 50 mM Hepes, pH 7.4. Alternatively, 18 hr after stimulation cleavage of Poly (ADP Ribose) Polymerase (PARP) was measured by Western blot (150,000 cells/25 mm^2^ flask, grown for 30 hr and stimulated for 18 hr) or immunocytochemistry (30, 000 cells/cover slip, grown for 30 hr and stimulated for 18 hr) as described above using an antibody specifically detecting cleaved PARP (Asp124, 1:500 for WB, 1:100 for ICC; Cell Signaling). An antibody against GAPDH (1:500; Santa Cruz Biotechnology) served as loading control for Western blot, the immunocytochemistry signal obtained by fluorescence microscopy was measured and normalized to the nuclear area yielding OD/nucleus area.

Statistical analysis {#s4-12}
--------------------

Values are given as means ± standard deviations (SD) of independent biological replicates, respectively. Diamonds shown in figures correspond to the data of an independent biological replicate, which means the experiment was performed with cells of a different subculture at a different time point. Statistical significance was analyzed by a two-tailed Student's t-test. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled \"Transmembrane chemokines act as receptors in a novel mechanism termed inverse signaling\" for peer review at *eLife*. Your submission has been favorably evaluated by Charles Sawyers (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

Hattermann and colleagues describe results from a series of studies investigating the role of trans membrane chemokines CXCL1 and 16 to signal in a novel transmembrane mechanism. The authors provide data that shed chemokines can act in an autocrine and/or paracrine manner. They termed this mechanism \"inverse\" signaling. They put these results in the context of tumor biology and suggest it is a previously unrecognized of cell to cell communication. The signaling mechanism identified is novel, with a wealth of evidence of its functionality in vitro, in several cell line models. Cells negative for the classical receptors respond with the soluble chemokines in the presence of the membrane bound forms, non-responsive cells will respond to the soluble chemokines after transfecting the cells with the transmembrane forms, and inactivating the transmembrane forms by deleting their c-terminus, responsible for the intracellular domain diminish the signal transduction. Furthermore the authors showed the binding of the soluble forms to the transmembrane forms, and also other evidence for the novel signaling is provided.

Essential revisions:

Overall, the studies are well described and performed. Clearly, the results are novel and will likely be of interest. All three reviewers agreed on the interest in the studies and the potential significance of the findings. The biggest criticism is that no parallel in vivo data is provided. This is somewhat limiting, especially as the authors discuss the results in the context of tumor biology. Ideally this could be addressed with experimental evidence. At a minimum, this needs to be put in better context.

There were a few concerns raised about the in vitro studies that need to be addressed.

1\) Why are the levels of the CXCL16 and CX3CL1 similar in all cells where they are expressed, like the signal is on/off- type?

2\) Why would all cell types respond with equal robust readouts? No cell-specific responses were provided, and I feel this to a bit odd.

3\) [Figure 4C](#fig4){ref-type="fig"} -- In contrast to the stated conclusion, inhibition of CXCR7 appears to block the effects of the soluble chemokines (as there is not much more ERK phosphorylation compared with control when treated with inhibitor, compared with when the cells are treated with vehicle). I would advise repeating this assay to establish their conclusion with certainty.

This is a bit concerning because CXCR7 is a canonical receptor and its blockade should have no effect whatsoever since the whole premise of the paper is that canonical receptors are *not* required for inverse signaling. Thus it might be important to get them to sort this out.
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Author response

*Essential revisions:*

Overall, the studies are well described and performed. Clearly, the results are novel and will likely be of interest. All three reviewers agreed on the interest in the studies and the potential significance of the findings. The biggest criticism is that no parallel in vivo data is provided. This is somewhat limiting, especially as the authors discuss the results in the context of tumor biology. Ideally this could be addressed with experimental evidence. At a minimum, this needs to be put in better context. There were a few concerns raised about the in vitro studies that need to be addressed. 1) Why are the levels of the CXCL16 and CX3CL1 similar in all cells where they are expressed, like the signal is on/off- type?

This question is indeed very interesting as this point might hint to a tissue/environment specific restriction of the "inverse signaling" and is therefore linked to the next reviewers' comment. To address this question (expression of *tm-*chemokines = on/off?), we now show more ICC stainings for CXCL16 and CX3CL1 of selected cell lines in the bottom of [Figure 1](#fig1){ref-type="fig"}. These micrographs clearly indicate that expression levels are different in the respective (tumor) cell lines: while the brain tumor cell lines (glioma, neuroblastoma) show strong expression patterns, the breast cancer cell line MCF-7 shows only slight protein expression of the transmembrane chemokines. The LOX melanoma cell line does not express CXCL16 or CX3CL1 on protein level. Corresponding text passages have been added to the Results and the figure legend. Thus, protein expression corresponds to the mRNA expression levels obtained by qRT-PCR. However, these data are presented in a log-scale in [Figure 1](#fig1){ref-type="fig"} (top). Thus, expression differences shown in the graph appear to be smaller than they are. To facilitate the readability of these data, we have added an explanation on ΔC~T~ values (a 3.33 alteration of ΔC~T~ value corresponds to a ten-fold altered expression) in this part of the Results section.

Together with the reviewers' next comment on the cell specificity of the cellular responses this comment led us to the obvious question if the low but detectable expression level of MCF-7 cells affects the existence and dimension of the inverse signaling. Thus, we have performed some additional experiments addressing the activation of the MAP kinase pathway and the rescue from apoptosis also with MCF-7 cells, and added the respective results to the Supplementary material (Figure 3---figure supplement 2). Indeed, the *tm*-chemokine low expressing cell line MCF-7 shows only slight activation of MAP kinase signaling upon stimulation with *s*-chemokines, and the rescue from apoptosis is only mild, and hardly robust.

On this note, the data hint to a cell type specific expression strength rather than emphasizing an on/off signal. This is also supported by observations by us and others that both *tm*-chemokines are induced by pro-inflammatory cytokines, and therefore can be regulated by environmental conditions. A corresponding remark citing some examples in the literature has been added to the Discussion.

*2) Why would all cell types respond with equal robust readouts? No cell-specific responses were provided, and I feel this to a bit odd.*

This point is -- as already explained above -- related to the previous point as a specific response may on the one hand depend on the cell type or on the other hand on the respective expression level. Concerning different cell lines, we see different activation kinetics of the MAP kinase in different glioma cell lines upon stimulation with the *s*-chemokines (compare [Figure 2](#fig2){ref-type="fig"}). To, however, more properly address the raised concern, we performed stimulation experiments with a breast cancer cell line, MCF-7, expressing low levels of *tm*-chemokines. As mentioned above, this cell line showed also activation of the MAP kinase pathway and a rescue from apoptosis. However, these effects were clearly smaller and less robust in comparison to the *tm*-chemokine high expressing glioma cell lines. These data were added as supplementary material to [Figure 3](#fig3){ref-type="fig"} (Figure 3---figure supplement 2), and a note was added to the Results.

Apart from this, in a separate manuscript, we show responses and effects of "inverse signaling" in meningioma cells that closely mirror the cellular effects of glioma cells as described in this manuscript. Briefly, primary human meningioma cells (meningioma: benign brain tumor descending from the meninges) showed activation of the MAP kinase pathway, enhanced proliferation and a reduction of caspase activity upon stimulation with CXCL16.

Taken together, our data emphasize an activation of the MAP kinase pathway and anti-apoptotic/proliferative effects of the "inverse signaling" of *tm*-chemokines that depends on the expression level of the *tm*-chemokines rather than the respective (tumor) cell type.

*3) [Figure 4C](#fig4){ref-type="fig"} -- In contrast to the stated conclusion, inhibition of CXCR7 appears to block the effects of the soluble chemokines (as there is not much more ERK phosphorylation compared with control when treated with inhibitor, compared with when the cells are treated with vehicle). I would advise repeating this assay to establish their conclusion with certainty.*

*This is a bit concerning because CXCR7 is a canonical receptor and its blockade should have no effect whatsoever since the whole premise of the paper is that canonical receptors are not required for inverse signaling. Thus it might be important to get them to sort this out.*

To more substantiate this, we replaced the western blot in [Figure 4C](#fig4){ref-type="fig"} with a more convincing experiment, and added replications of this experiment to the supplementary figures ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Additionally, to explain the phenomenon of non-canonical chemokine receptor signaling for a broader readership we have addressed this point in the Discussion.

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.

[^3]: Data from: Uniprot (<http://www.uniprot.org/>).

[^4]: <http://www.uniprot.org/uniprot/?query=CX3CL1&sort=score>.

[^5]: <http://www.uniprot.org/uniprot/?query=CXCL16&sort=score>.

[^6]: Putative intracellular domains are depicted by homology to the published putative human sequences.

[^7]: [**-SXXS-**]{.ul} motifs, **-SXXT-** motifs, *-SXS-* motifs; ***-SXPV/R-*** SH2-binding site.
